rotenone has been researched along with Parkinson Disease, Secondary in 147 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.36) | 18.2507 |
| 2000's | 33 (22.45) | 29.6817 |
| 2010's | 78 (53.06) | 24.3611 |
| 2020's | 34 (23.13) | 2.80 |
| Authors | Studies |
|---|---|
| Akinina, AI; Kryl'skii, ED; Nihaev, LE; Potapova, TN; Razuvaev, GA | 1 |
| Afzal, A; Ahmad, S; Batool, Z; Haider, S; Liaquat, L; Madiha, S; Naqvi, F; Nawaz, A; Sadir, S; Sajid, I; Saleem, S; Shahzad, S; Tabassum, S; Yousuf, S | 1 |
| El-Naga, RN; Mohamad, KA; Wahdan, SA | 1 |
| Chen, Z; Li, H; Li, Z; Shen, L; Sun, B; Yang, J; Zhang, J; Zhang, N | 1 |
| Sakamula, R; Thong-Asa, W; Yata, T | 1 |
| Bian, LH; Guo, JY; Li, JY; Li, QY; Shi, JL; Wan, GH; Wang, XM; Wang, YQ; Wang, ZY; Wei, XJ; Yang, X; Yao, ZW | 1 |
| Ahmed, MK; Budzyńska, B; El Sayed, NS; Kandil, EA; Sayed, AS; Skalicka-Woźniak, K | 1 |
| Abd El Fattah, MA; Ahmed, LA; El-Sayeh, BM; Kandil, EA; Sayed, RH | 1 |
| Cheng, J; Li, H; Liu, Q; Wang, F; Wang, Y; Yang, J | 1 |
| Chen, Q; Jiang, X; Sun, Y; Yu, BC; Zhang, X | 1 |
| Raj, K; Sharma, S; Singh, S | 1 |
| Hu, WT; Ji, YF; Liu, X; Lu, H; Sun, GF; Tian, T; Wang, JP; Wang, MH; Yang, HC; Zhang, LM | 1 |
| Abbas, SS; Abdel-Latif, GA; El Magdoub, HM; Salama, RM; Schaalan, MF | 1 |
| Ahmed, YR; Ali, SA; Hamed, MA; Khalil, WKB; Motawi, TK; Sadik, NAH | 1 |
| Mahdi, AA; Pandey, S; Rumman, M; Singh, B | 1 |
| Chen, J; Ge, X; Huang, W; Shao, Q; Xu, Z; Yang, Y; Zhang, X | 1 |
| Akamatsu, W; Hattori, N; Imoto, M; Ishikawa, KI; Kataura, T; Saiki, S; Sasazawa, Y | 1 |
| Chen, AD; Jing, YH; Wang, DX; Wang, QJ; Xin, YY; Yin, J | 1 |
| Jauhari, A; Mishra, S; Shankar, J; Singh, T; Yadav, S | 1 |
| Adedara, IA; Adeniyi, PA; Agedah, AE; Akindoyeni, IA; Awogbindin, IO; Ezekiel, OG; Farombi, EO; Mustapha, YE; Ogbuewu, E; Olorunkalu, PD; Oyetunde, BF | 1 |
| Batool, Z; Haider, S; Madiha, S | 1 |
| Chen, J; Cheng, Q; Ding, F; Guo, H; Guo, XY; Lu, JL; Shi, Y; Yu, S; Zhang, Q; Zhang, Y; Zhou, J | 1 |
| Chang, A; Dastidar, SG; Jordan, S; La Spada, AR; Mitchell, MB; Pham, MT; Sopher, BL; Yeom, SG | 1 |
| Brown, MR; Carla Carisi, M; Davies, JS; Morgan, AH; Rees, DJ; Roberts, L | 1 |
| Abdelrahman, A; Ahmed, OG; Mahmoud, ME; Monir, DM; Rehan, IF | 1 |
| Berezhnoy, DS; Fedorova, TN; Nalobin, DS; Troshev, DV | 1 |
| Harish Prashanth, KV; Pramod Kumar, P | 1 |
| Balakrishnan, R; Choi, DK; Elangovan, N; Ganesan, P; Manimaran, D; Mohankumar, T; Vijayraja, D | 1 |
| Abdel Hafez, SMN; Abdelwahab, SA; Elsebay, SAG; Ibrahim, MFG | 1 |
| Avcı, B; Bilge, SS; Günaydın, C; Güvenç, T; Kuruca, N; Yavuz, CK | 1 |
| Imaishi, H; Imaoka, S; Ishida, A; Ishihara, Y; Oguro, A; Siswanto, FM; Yamazaki, T | 1 |
| Agostini, JF; Calisto, JFF; de Sá Fonseca, V; de Veras, BO; Magro, JD; Mocelin, R; Rico, E; Santo, GD; Vieira, LD; Wanderley, AG | 1 |
| Gu, J; Song, G; Sun, X; Wang, K; Yu, Y; Yuan, X; Zhang, K; Zhang, L; Zhang, Z | 1 |
| Abaimov, D; Berezhnoy, D; Fedorova, T; Kulikova, O; Muzychuk, O; Nalobin, D; Stvolinsky, S; Troshev, D | 1 |
| Date, AA; Kalaria, D; Kalia, Y; Patel, P; Patravale, V; Pol, A | 1 |
| Corbo, M; Feligioni, M; Hassanzadeh, K; Izadpanah, E; Maccarone, R; Moloudi, MR; Rahimmi, A | 1 |
| Adem, A; Azimullah, S; Beiram, R; Jalal, FY; Jayaraj, RL; M F, NM; Ojha, SK | 1 |
| Fu, L; Han, B; Han, Y; He, J; Li, C; Wang, T; Wang, Z; Zhao, Y | 1 |
| Chidambaram, R; Dhanalakshmi, C; Essa, MM; Justin Thenmozhi, A; Kalandar, A; Manivasagam, T; Rajasankar, S; Ramkumar, M; Venkatesh Gobi, V | 1 |
| Batool, Z; Haider, S; Liaquat, L; Madiha, S; Perveen, T; Sadir, S; Shahzad, S; Tabassum, S | 1 |
| Bajaj, A; Gaud, R; Meshram, P; Sridhar, V; Wairkar, S | 1 |
| Badalyan, SA; Chavushyan, VA; Darbinyan, LV; Hambardzumyan, LE; Khalaji, N; Manukyan, LP; Sarkisian, VH; Simonyan, KV | 1 |
| Du, G; Du, L; Yang, Y; Zhang, W; Zhang, X; Zhou, Q | 1 |
| Charkhat Gorgich, EA; Khajavi, O; Komeili, G; Salimi, S; Sarbishegi, M | 1 |
| Bao, Z; Chao, H; Fu, X; Ji, J; Li, Z; Lin, C; Liu, N; Liu, Y; Wang, X; Xu, X; You, Y | 1 |
| Babu, B; Hammock, BD; Hwang, SH; Krishnamurthy, PT; Lakkappa, N; Yamjala, K | 1 |
| Ivanov, MV; Khudoerkov, RM; Kutukova, KA; Voronkov, DN | 1 |
| Ivanova, EA; Kapitsa, IG; Pozdnev, VF; Valdman, EA; Voronina, TA; Zolotov, NN | 1 |
| Cao, J; Dan, G; Hu, J; Peng, K; Sai, Y; Xiao, J; Yang, L; Ye, F; Zou, Z | 1 |
| Bobrovskaya, L; Johnson, ME; Stringer, A | 1 |
| Achilli, A; Caporali, L; Carelli, V; Ghelli, A; Iommarini, L; Maresca, A; Martinuzzi, A; Montopoli, M; Olivieri, A; Strobbe, D; Torroni, A | 1 |
| Ashraf, GM; Barreto, GE; Cabezas, R; Díaz, JE; Echeverria, V; González, J; Jurado-Coronel, JC; Loaiza, AE; Sahebkar, A | 1 |
| Ahmed, A; El-Sayed, EK; Morsy, EE; Nofal, S | 1 |
| Capps, J; Virga, DM; Vohra, BPS | 1 |
| Ayton, D; Ayton, S; Barker, AL; Bush, AI; Warren, N | 1 |
| Lee, JC; Moon, MH; Yang, JS | 1 |
| Hemalatha, P; Muralidhara, M; Rajini, PS; Rao, SV; Yetish, S | 1 |
| Ajayi, AM; Alabi, AO; Bakre, AG; Ben-Azu, B; Umukoro, S | 1 |
| Chen, Z; Ghoorah, D; Hou, L; Huang, J; Jia, M; Lin, Z; Liu, L; Luo, Z; Wang, T; Xiong, J; Xiong, N; Zhang, X; Zhang, Z | 1 |
| Lenaers, G; Reynier, P; Thany, SH | 1 |
| Ahmad, ST; O'Brien, LM; St Laurent, R | 1 |
| Gupta, SP; Mishra, SK; Singh, MP; Singhal, NK; Tiwari, MN; Yadav, S | 1 |
| Kamel, F | 1 |
| Chen, D; Gao, F; Hu, Q; Wang, G | 1 |
| Ambasta, RK; Anand, K; Kumar, P; Sarkar, A; Sonia Angeline, M | 1 |
| Chen, J; Chen, Y; Huang, J; Lao, W; Li, X; Wang, H; Wang, T; Zhang, Z | 1 |
| Jagota, A; Mattam, U | 1 |
| Kostrzewa, RM; Segura-Aguilar, J | 1 |
| Cooney, A; Goldstein, DS; Jinsmaa, Y; Kopin, IJ; Sharabi, Y; Sullivan, P | 1 |
| Abdelsalam, RM; Safar, MM | 1 |
| Calogero, A; Cappelletti, G; Cartelli, D; Casagrande, F; De Gregorio, C; Pezzoli, G | 1 |
| Asanuma, M; Miyazaki, I; Miyoshi, K; Murakami, S | 1 |
| Guan, JJ; Hou, YS; Qin, ZH; Sheng, R; Wu, F; Xu, HD | 1 |
| Nikonenko, AG; Voitenko, LP | 1 |
| Ding, F; Dong, X; Gao, X; Ji, J; Qin, J; Wu, M; Yu, S; Zhang, J; Zhang, Q; Zhang, Y; Zhou, L | 1 |
| Dowd, E; Feehan, J; Moriarty, N; Naughton, C; O'Toole, D | 1 |
| Chen, NH; Chu, SF; Guo, QL; Huang, JY; Shi, JG; Wang, YN; Yan, JQ; Yuan, YH; Zhu, CG | 1 |
| Azimullah, S; Haque, ME; Javed, H; Ojha, S | 1 |
| Hu, Q; Huang, M; Jiang, H; Kang, H; Lian, L; Liang, Q; Liu, A; Liu, X; Pan-Montojo, F; Uversky, VN; Xu, F; Zhang, C; Zhu, S | 1 |
| Chompoopong, S; Chongthammakun, S; Jarungjitaree, S; Kettawan, A; Punbanlaem, T; Rungruang, T; Taechowisan, T | 1 |
| Ablat, N; Han, H; Lei, H; Lv, D; Ma, X; Ma, Y; Pu, X; Qi, X; Ren, R; Sun, Y; Xiaokaiti, Y; Xu, F; Xu, J; Ye, M; Zhao, X | 1 |
| Chen, M; Duan, C; Gao, G; Liu, J; Lu, L; Wang, X; Wang, Y; Wu, X; Yang, H | 1 |
| Feng, D; Gong, J; He, X; Ji, J; Jin, T; Li, L; Liu, C; Sun, H; Sun, J; Xiang, L; Yue, S; Zhou, R | 1 |
| Boyd, J; Han, A | 1 |
| Hu, LF; Liu, CF; Liu, W; Sima, Y; Wang, F; Wang, H; Wang, Y; Yang, J; Zhong, ZM | 1 |
| Aboul Ezz, HS; Khadrawy, YA; Mohammed, HS; Mourad, IM; Noor, NA | 1 |
| Ascenzi, P; Beltrami, AP; Bertuzzi, M; Cesselli, D; Codrich, M; Espinoza, S; Francescatto, M; Giacca, M; Gustincich, S; Leanza, G; Persichetti, F; Russo, R; Zentilin, L; Zucchelli, S | 1 |
| Chen, Y; Jing, X; Lei, M; Liang, Y; Lin, D; Liu, J; Peng, S; Tao, E; Wu, X; Xiao, S; Yang, L; Zeng, Z; Zheng, D; Zhou, T | 1 |
| Hanpude, P; Jangir, DK; Kanti Maiti, T; Kumar, R; Kumar, S; Kumari, R; Ranjan Jana, N; Sarovar Bhavesh, N; Shekhar, S; Singh, N; Verma, G | 1 |
| Chen, SD; Shen, CY; Wang, G; Wang, ZQ; Zeng, J | 1 |
| Cai, GJ; Liu, JG; Shen, FM; Su, DF; Wu, J; Yu, JG | 1 |
| Anderson, M; Betarbet, R; Cheng, D; Chu, CT; Gearing, M; Greenamyre, JT; Gutekunst, CA; Hoffman, EK; Horowitz, MP; Mastroberardino, PG; Na, HM; Peng, J; Taylor, G; Trojanowski, JQ | 1 |
| Shimohama, S | 1 |
| Allen, AL; Luo, C; Montgomery, DL; Rajput, A; Rajput, AH; Robinson, CA | 1 |
| Greene, JG; Noorian, AR; Srinivasan, S | 1 |
| Chung, JH; Kim, HJ; Park, HJ; Park, HK | 1 |
| Ambrosini, MV; Calabresi, P; Luchetti, E; Mariucci, G; Spaccatini, C; Taha, E; Tantucci, M; Tozzi, A | 1 |
| Contestabile, A; Gatta, V; Monti, B; Piretti, F; Raffaelli, SS; Virgili, M | 1 |
| Cicchetti, F; Drouin-Ouellet, J; Gross, RE | 1 |
| Bian, JS; Dawe, GS; Hu, G; Hu, LF; Lu, M; Tiong, CX | 1 |
| Cannon, JR; Drolet, R; Greenamyre, JT; Mastroberardino, PG | 1 |
| Andreatini, R; Barbieiro, J; Dombrowski, PA; Lima, MM; Santiago, RM; Vital, MA | 1 |
| Mackay-Sim, A; Meedeniya, AC; Nguyen, MN; Norazit, A | 1 |
| Cannon, JR; Greenamyre, JT | 1 |
| Goldberg, MS; Ju, X; Li, W; Liu, R; Mao, Z; Marvin, MA; Poteet, EC; Qian, H; She, H; Simpkins, JW; Tan, C; Wen, Y; Xie, L; Yan, LJ; Yang, SH | 1 |
| Chauhan, S; Kaur, H; Sandhir, R | 1 |
| Celik, T; Gürsoy, M; Isik, AT; Kayir, H; Ulusoy, GK; Uzbay, TI | 1 |
| Spivey, A | 1 |
| Hanif, A; Nash, JE; Perera, G; Sidorova, E; Yong-Kee, CJ | 1 |
| Chen, NH; Hu, JF; Li, BY; Yuan, YH; Zhang, DM; Zhao, Q | 1 |
| Bové, J; Perier, C | 1 |
| Dowd, E; Kirik, D; Mulcahy, P; O'Brien, T; O'Doherty, A; Paucard, A | 1 |
| Tieu, K | 1 |
| Chesselet, MF; McDowell, K | 1 |
| Akaike, A; Hongo, H; Izumi, Y; Kihara, T; Kume, T; Niidome, T; Sugimoto, H | 1 |
| Chen, SD; Cheng, CH; Chuang, YC; Huang, CR; Lin, TK; Liou, CW | 1 |
| Nehru, B; Thakur, P | 1 |
| Arnhold, M; Funk, RH; Gille, G; Marsico, G; O'Sullivan, GA; Pal, A; Pan-Montojo, F; Reichmann, H; Rodrigo-Angulo, M; Said, J; Schwarz, M; Verbavatz, JM; Winkler, C | 1 |
| Andreatini, R; Ariza, D; Barbiero, JK; Lima, MM; Martynhak, BJ; Morais, LH; Santiago, R; Takahashi, TT; Vital, MA | 1 |
| Sanders, LH; Timothy Greenamyre, J | 1 |
| Liu, Q; Peng, J; Rao, MS; Zeng, X | 1 |
| Baptista, M; Betarbet, R; Cookson, MR; Greenamyre, JT; Lund, S; Panov, AV; Sherer, TB; Stout, AK | 1 |
| Tai, KK; Truong, DD | 1 |
| Bonetta, L | 1 |
| Alam, M; Schmidt, WJ | 2 |
| Kotake, Y; Ohta, S | 1 |
| Blanchet, J; Cicchetti, F; Gould, P; Lapointe, N; Martinoli, MG; Rouillard, C; St-Hilaire, M | 1 |
| Brown, R; Cussen, V; García-García, F; Krueger, JM; Ponce, S | 1 |
| Bové, J; Perier, C; Prou, D; Przedborski, S | 1 |
| Baranyi, M; Milusheva, E; Sperlágh, B; Vizi, ES | 1 |
| Caparros-Lefebvre, D; Kotake, Y; Ohta, S; Steele, J | 1 |
| Baumeister, R; Braungart, E; Gerlach, M; Hoener, MC; Riederer, P | 1 |
| Imamura, K; Kashiwaya, Y; Nakashima, K; Nakaso, K; Takeshima, T | 1 |
| Hirsch, EC; Höglinger, GU; Oertel, WH | 1 |
| Ayala, A; Cano, J; Machado, A; Venero, JL | 1 |
| Bandez, MJ; Gomez, C; Navarro, A | 1 |
| Cavada, C; Cuadrado, A; de Sagarra, MR; Rojo, AI | 1 |
| Griffiths, HR; Lunec, J; Willets, JM; Williams, AC | 1 |
| Duan, W; Mattson, MP | 1 |
| Burkhardt, K; Kaftan, A; Schwarz, J; Storch, A | 1 |
| Adam, D | 1 |
| Giasson, BI; Lee, VM | 1 |
| Betarbet, R; Garcia-Osuna, M; Greenamyre, JT; MacKenzie, G; Panov, AV; Sherer, TB | 1 |
| Morris, S; Powell, D | 1 |
| Cadet, JL; Cutler, RG; Duan, W; Kruman, II; Ladenheim, B; Mattson, MP | 1 |
| Aschner, M; Seegal, RF | 1 |
17 review(s) available for rotenone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Does restraining nitric oxide biosynthesis rescue from toxins-induced parkinsonism and sporadic Parkinson's disease?
Topics: Animals; Humans; Methamphetamine; Nitric Oxide; Nitric Oxide Synthase; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Parkinsonian Disorders; Reactive Nitrogen Species; Rotenone | 2014 |
Linking microtubules to Parkinson's disease: the case of parkin.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Synuclein; Animals; Disease Models, Animal; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mice; Microtubules; Mutation; Neurons; Parkinson Disease, Secondary; Protein Serine-Threonine Kinases; Rotenone; Tubulin; Ubiquitin-Protein Ligases | 2015 |
Deguelin and Its Role in Chronic Diseases.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Chronic Disease; Disease Models, Animal; Drug Discovery; Electron Transport Complex I; Enzyme Inhibitors; Humans; Molecular Structure; Parkinson Disease, Secondary; Phytotherapy; Plants, Medicinal; Risk Factors; Rotenone; Signal Transduction | 2016 |
Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Amyloid beta-Peptides; Animals; Drug Synergism; Galantamine; Glutamic Acid; Motor Neurons; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Nicotine; Nicotinic Agonists; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylinositol 3-Kinases; Rats; Receptors, Nicotinic; Rotenone; Signal Transduction; Spinal Cord | 2009 |
Environmental toxins and Parkinson's disease: what have we learned from pesticide-induced animal models?
Topics: Animals; Disease Models, Animal; Environmental Exposure; Humans; Maneb; Paraquat; Parkinson Disease, Secondary; Pesticides; Rotenone | 2009 |
Lessons from the rotenone model of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Environmental Exposure; Humans; Parkinson Disease; Parkinson Disease, Secondary; Rotenone | 2010 |
Neurotoxic in vivo models of Parkinson's disease recent advances.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; MPTP Poisoning; Neurotoxicity Syndromes; Neurotoxins; Oxidopamine; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Rotenone; Sympatholytics; Uncoupling Agents | 2010 |
Neurotoxin-based models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Cell Death; Disease Models, Animal; Neurotoxins; Oxidopamine; Paraquat; Parkinson Disease, Secondary; Rotenone | 2012 |
A guide to neurotoxic animal models of Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Haplorhini; Lewy Bodies; Mice; MPTP Poisoning; Neurotoxins; Oxidopamine; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rotenone; Substantia Nigra | 2011 |
Animal models of the non-motor features of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Disease Models, Animal; Humans; Hydroxydopamines; MPTP Poisoning; Neurotoxins; Parkinson Disease; Parkinson Disease, Secondary; Risk Factors; Rotenone; Uncoupling Agents | 2012 |
Oxidative damage to macromolecules in human Parkinson disease and the rotenone model.
Topics: Animals; Disease Models, Animal; DNA Damage; Dopaminergic Neurons; Humans; Lipid Metabolism; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Proteins; Rotenone | 2013 |
MPP+ analogs acting on mitochondria and inducing neuro-degeneration.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Electron Transport; Humans; Isoquinolines; Mitochondria; Neurodegenerative Diseases; Neurons; Parkinson Disease, Secondary; Rotenone; Ubiquinone; Uncoupling Agents | 2003 |
Toxin-induced models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Herbicides; Humans; Neurotoxins; Oxidative Stress; Oxidopamine; Paraquat; Parkinson Disease, Secondary; Rotenone; Sympatholytics | 2005 |
The rotenone model of parkinsonism--the five years inspection.
Topics: Animals; Disease Models, Animal; Dopamine; Humans; Movement; Neurodegenerative Diseases; Neurons; Parkinson Disease, Secondary; Rotenone; Substantia Nigra; tau Proteins; Uncoupling Agents | 2006 |
Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine; Dopamine Agents; Humans; Nerve Degeneration; Oxidopamine; Parkinson Disease, Secondary; Rotenone; Uncoupling Agents | 2006 |
Mitochondrial toxins and neurodegenerative diseases.
Topics: Animals; Disease Models, Animal; Humans; Huntington Disease; Mitochondria; MPTP Poisoning; Neurodegenerative Diseases; Nitro Compounds; Parkinson Disease, Secondary; Propionates; Rotenone; Succinate Dehydrogenase; Tetrahydroisoquinolines | 2007 |
Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome.
Topics: Animals; Free Radicals; Humans; Mitochondria; Nitric Oxide; Paraquat; Parkinson Disease, Secondary; Pesticides; Pyridazines; Rats; Rotenone | 2007 |
130 other study(ies) available for rotenone and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Functioning of the Antioxidant Defense System in Rotenone-Induced Parkinson's Disease.
Topics: Animals; Antioxidants; Brain; Catalase; Gene Expression; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Male; Mitochondria; Oxidative Stress; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Superoxide Dismutase | 2021 |
Quercetin exhibits potent antioxidant activity, restores motor and non-motor deficits induced by rotenone toxicity.
Topics: Animals; Antioxidants; Behavior, Animal; Cognition; Cognitive Dysfunction; Depression; Disease Models, Animal; Male; Motor Activity; Neuroprotective Agents; Neurotransmitter Agents; Oxidative Stress; Parkinson Disease, Secondary; Quercetin; Rats; Rats, Wistar; Rotenone; Signal Transduction; Treatment Outcome | 2021 |
Neuroprotective effects of indole-3-carbinol on the rotenone rat model of Parkinson's disease: Impact of the SIRT1-AMPK signaling pathway.
Topics: alpha-Synuclein; Animals; Body Weight; Catalepsy; Dopamine; Indoles; Male; MAP Kinase Signaling System; Motor Activity; Neostriatum; Neuroprotective Agents; Parkinson Disease, Secondary; Postural Balance; Rats; Rats, Sprague-Dawley; Rotenone; Sirtuin 1; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2022 |
Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Avoidance Learning; Blotting, Western; Chronic Disease; Disease Models, Animal; DNA-Binding Proteins; Dopaminergic Neurons; Glial Fibrillary Acidic Protein; Humans; Immunohistochemistry; Mice, Inbred C57BL; Motor Activity; Nerve Tissue Proteins; Parkinson Disease, Secondary; Rotenone; Substantia Nigra; Tyrosine 3-Monooxygenase | 2022 |
Nanostructure lipid carriers enhance alpha-mangostin neuroprotective efficacy in mice with rotenone-induced neurodegeneration.
Topics: Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Lipids; Male; Mice; Mice, Inbred ICR; Nanostructures; Neuroprotective Agents; Parkinson Disease, Secondary; Rotenone; Substantia Nigra; Superoxide Dismutase; Tissue Distribution; Tyrosine 3-Monooxygenase; Xanthones | 2022 |
Nardosinone regulates the slc38a2 gene to alleviate Parkinson's symptoms in rats through the GABAergic synaptic and cAMP pathways.
Topics: Animals; Parkinson Disease; Parkinson Disease, Secondary; Polycyclic Sesquiterpenes; Rats; Rotenone | 2022 |
Xanthotoxin modulates oxidative stress, inflammation, and MAPK signaling in a rotenone-induced Parkinson's disease model.
Topics: alpha-Synuclein; Animals; Antioxidants; Dopamine; Dopaminergic Neurons; Inflammation; Methoxsalen; Mitogen-Activated Protein Kinases; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Signal Transduction | 2022 |
Hypoxia-inducible factor 1 alpha and nuclear-related receptor 1 as targets for neuroprotection by albendazole in a rat rotenone model of Parkinson's disease.
Topics: Albendazole; Animals; Behavior, Animal; Cell Death; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Molecular Targeted Therapy; Neuroprotection; Neuroprotective Agents; Nuclear Receptor Subfamily 4, Group A, Member 2; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone | 2019 |
Neuroprotective effects of increasing levels of HSP70 against neuroinflammation in Parkinson's disease model by inhibition of NF-κB and STAT3.
Topics: Apoptosis; Cell Line; Down-Regulation; HSP70 Heat-Shock Proteins; Humans; Inflammation; Neuroprotective Agents; NF-kappa B; Parkinson Disease, Secondary; RNA, Messenger; Rotenone; STAT3 Transcription Factor | 2019 |
Cordycepin Exerts Neuroprotective Effects via an Anti-Apoptotic Mechanism based on the Mitochondrial Pathway in a Rotenone-Induced Parkinsonism Rat Model.
Topics: Animals; Apoptosis; Deoxyadenosines; Dopaminergic Neurons; Membrane Potential, Mitochondrial; Mitochondria; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Pars Compacta; Rats; Rotenone; Tyrosine 3-Monooxygenase | 2019 |
Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats.
Topics: Alkaloids; Benzodioxoles; Corpus Striatum; Dietary Supplements; Drug Synergism; Electron Transport Complex I; Electron Transport Complex IV; Glutathione; Indoles; Interleukin-1beta; Interleukin-6; Iron; Lipid Peroxidation; Neuroprotective Agents; Neurotransmitter Agents; Nitrites; Parkinson Disease, Secondary; Piperidines; Polyunsaturated Alkamides; Quercetin; Rotenone; Tumor Necrosis Factor-alpha | 2020 |
Dopaminergic neuron injury in Parkinson's disease is mitigated by interfering lncRNA SNHG14 expression to regulate the miR-133b/ α-synuclein pathway.
Topics: alpha-Synuclein; Animals; Cell Line; Disease Models, Animal; Dopaminergic Neurons; Intracellular Signaling Peptides and Proteins; Mice, Inbred C57BL; MicroRNAs; Nerve Tissue Proteins; Parkinson Disease, Secondary; RNA, Long Noncoding; Rotenone | 2019 |
Neuroprotective effect of crocin against rotenone-induced Parkinson's disease in rats: Interplay between PI3K/Akt/mTOR signaling pathway and enhanced expression of miRNA-7 and miRNA-221.
Topics: Animals; Behavior, Animal; Carotenoids; Male; MicroRNAs; Neuroprotective Agents; Oncogene Protein v-akt; Parkinson Disease, Secondary; Phosphatidylinositol 3-Kinases; Rats; Rats, Wistar; Rotenone; Signal Transduction; TOR Serine-Threonine Kinases; Uncoupling Agents; Weight Loss | 2020 |
Potential therapeutic effects of antagonizing adenosine A
Topics: Adenosine A2 Receptor Antagonists; Animals; Curcumin; Disease Models, Animal; Hippocampus; Humans; Male; Mice; Neuroprotective Agents; Niacin; Parkinson Disease, Secondary; Receptor, Adenosine A2A; Rotenone; Substantia Nigra | 2020 |
Neuroprotective effects of Bacopa monnieri in Parkinson's disease model.
Topics: alpha-Synuclein; Animals; Bacopa; Cerebral Cortex; Chemokine CCL4; Disease Models, Animal; Hippocampus; Interleukin-1beta; Interleukin-6; Male; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Plant Extracts; Rats; Rats, Wistar; Reactive Oxygen Species; Rotenone; Substantia Nigra; Tumor Necrosis Factor-alpha | 2020 |
Drp1, a potential therapeutic target for Parkinson's disease, is involved in olfactory bulb pathological alteration in the Rotenone-induced rat model.
Topics: Animals; Dynamins; Inflammasomes; Male; Mitochondria; Movement Disorders; Neurons; NF-kappa B; Nitric Oxide Synthase Type II; NLR Family, Pyrin Domain-Containing 3 Protein; Olfactory Bulb; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Smell; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2020 |
BRUP-1, an intracellular bilirubin modulator, exerts neuroprotective activity in a cellular Parkinson's disease model.
Topics: Animals; Bilirubin; Gene Silencing; Heme Oxygenase-1; Hep G2 Cells; Humans; Induced Pluripotent Stem Cells; Kelch-Like ECH-Associated Protein 1; Neuroprotective Agents; Neurotoxins; NF-E2-Related Factor 2; Parkinson Disease, Secondary; PC12 Cells; Rats; Reactive Oxygen Species; RNA, Small Interfering; Rotenone; Uncoupling Agents | 2020 |
Protective effect of metformin against rotenone-induced parkinsonism in mice.
Topics: Animals; Behavior, Animal; Disease Models, Animal; Dopaminergic Neurons; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Inflammation; Interleukin-1beta; Male; Metformin; Mice; Mice, Inbred C57BL; Microglia; Parkinson Disease, Secondary; Protective Agents; Rotenone; Tumor Necrosis Factor-alpha | 2020 |
Coordinated Action of miR-146a and Parkin Gene Regulate Rotenone-induced Neurodegeneration.
Topics: Animals; Disease Models, Animal; MicroRNAs; Mitochondria; Mitophagy; NF-kappa B; Parkinson Disease, Secondary; Rats; Rotenone; Ubiquitin-Protein Ligases | 2020 |
Nigral and ventral tegmental area lesioning induces testicular and sperm morphological abnormalities in a rotenone model of Parkinson's disease.
Topics: Acetylcholinesterase; Animals; Dopaminergic Neurons; Male; Parkinson Disease, Secondary; Rats; Rotenone; Spermatozoa; Substantia Nigra; Testis; Ventral Tegmental Area | 2020 |
Amelioration of motor and non-motor deficits and increased striatal APoE levels highlight the beneficial role of pistachio supplementation in rotenone-induced rat model of PD.
Topics: Animals; Apolipoproteins E; Corpus Striatum; Disease Models, Animal; Motor Skills; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Pistacia; Plant Extracts; Rats; Rotenone | 2020 |
Pyrroloquinoline quinone promotes mitochondrial biogenesis in rotenone-induced Parkinson's disease model via AMPK activation.
Topics: AMP-Activated Protein Kinases; Animals; Behavior, Animal; Cell Line, Tumor; Humans; Locomotion; Male; Mice, Inbred ICR; Mitochondria; Nerve Tissue Proteins; Neuroprotective Agents; Organelle Biogenesis; Parkinson Disease, Secondary; Phosphorylation; PQQ Cofactor; Rotenone; Signal Transduction | 2021 |
4E-BP1 Protects Neurons from Misfolded Protein Stress and Parkinson's Disease Toxicity by Inducing the Mitochondrial Unfolded Protein Response.
Topics: Adaptor Proteins, Signal Transducing; alpha-Synuclein; Animals; Animals, Newborn; Brefeldin A; Cell Cycle Proteins; Female; Male; Mice; Mice, Transgenic; Mitochondria; Neurons; Parkinson Disease, Secondary; Primary Cell Culture; Protein Biosynthesis; Protein Synthesis Inhibitors; Protein Unfolding; Proteostasis Deficiencies; Rotenone; Uncoupling Agents | 2020 |
Automated Quantification of Mitochondrial Fragmentation in an In Vitro Parkinson's Disease Model.
Topics: Animals; Cell Culture Techniques; Dopaminergic Neurons; Image Processing, Computer-Assisted; Insecticides; Membrane Potential, Mitochondrial; Mice; Mitochondria; Parkinson Disease, Secondary; Rotenone | 2020 |
Forced exercise activates the NrF2 pathway in the striatum and ameliorates motor and behavioral manifestations of Parkinson's disease in rotenone-treated rats.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Gait Disorders, Neurologic; Levodopa; Male; Memory, Short-Term; Movement Disorders; Neostriatum; NF-E2-Related Factor 2; Parkinson Disease, Secondary; Physical Conditioning, Animal; Psychomotor Performance; Rats; Rats, Wistar; Rotenone; Signal Transduction; Tyrosine 3-Monooxygenase; Uncoupling Agents; Up-Regulation | 2020 |
Changes in COX histochemistry in the brain of mice and rats exposed to chronic subcutaneous rotenone.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Electron Transport Complex IV; Mice; Mitochondria; Neurons; Parkinson Disease, Secondary; Rats; Rotenone | 2020 |
Diet with Low Molecular Weight Chitosan exerts neuromodulation in Rotenone induced Drosophila model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Chitosan; Drosophila melanogaster; Insecticides; Male; Motor Activity; Neurotransmitter Agents; Oxidative Stress; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone | 2020 |
Isolongifolene mitigates rotenone-induced dopamine depletion and motor deficits through anti-oxidative and anti-apoptotic effects in a rat model of Parkinson's disease.
Topics: Animals; Apoptosis; Dopamine; Lipid Peroxidation; Male; Motor Activity; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Sesquiterpenes | 2021 |
Cerebral and cerebellar histological changes in the rat animal model of rotenone induced parkinsonism can be ameliorated by bone marrow derived stem cell conditioned media.
Topics: Animals; Behavior, Animal; Cerebellum; Cerebral Cortex; Culture Media, Conditioned; Disease Models, Animal; Mesenchymal Stem Cells; Motor Activity; Parkinson Disease, Secondary; Rats; Rotenone | 2021 |
Idebenone Ameliorates Rotenone-Induced Parkinson's Disease in Rats Through Decreasing Lipid Peroxidation.
Topics: Animals; Antioxidants; Brain; Dopaminergic Neurons; Lipid Peroxidation; Locomotion; Male; Neuroprotective Agents; Open Field Test; Parkinson Disease, Secondary; Rats, Sprague-Dawley; Rotenone; Ubiquinone | 2021 |
Contribution of DHA diols (19,20-DHDP) produced by cytochrome P450s and soluble epoxide hydrolase to the beneficial effects of DHA supplementation in the brains of rotenone-induced rat models of Parkinson's disease.
Topics: Animals; Brain; Catalase; Cytochrome P-450 Enzyme System; Disease Models, Animal; Docosahexaenoic Acids; Epoxide Hydrolases; Fatty Acids, Unsaturated; Humans; Male; Neuroprotective Agents; NF-E2-Related Factor 2; Oxidation-Reduction; Parkinson Disease, Secondary; Rats; Rotenone; Superoxide Dismutase-1 | 2021 |
Hexane extract from SpoSndias mombin L. (Anacardiaceae) prevents behavioral and oxidative status changes on model of Parkinson's disease in zebrafish.
Topics: Anacardiaceae; Animals; Behavior, Animal; Disease Models, Animal; Lipid Peroxidation; Oxidative Stress; Parkinson Disease, Secondary; Plant Extracts; Rotenone; Zebrafish | 2021 |
Hydrogen-saturated saline mediated neuroprotection through autophagy via PI3K/AKT/mTOR pathway in early and medium stages of rotenone-induced Parkinson's disease rats.
Topics: Animals; Autophagy; Hydrogen; Male; Neuroprotection; Neuroprotective Agents; Parkinson Disease, Secondary; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Rotenone; Signal Transduction; Sodium Chloride; TOR Serine-Threonine Kinases | 2021 |
The dynamics of nigrostriatal system damage and neurobehavioral changes in the rotenone rat model of Parkinson's disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopaminergic Neurons; Eating; Hand Strength; Male; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Substantia Nigra | 2021 |
Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Biological Availability; Disease Models, Animal; Emulsions; Feasibility Studies; Humans; Hydrogels; Indans; Locomotion; Male; Monoamine Oxidase Inhibitors; Parkinson Disease, Secondary; Rabbits; Rats; Rotenone; Skin; Skin Tests | 2021 |
Effect of lobeglitazone on motor function in rat model of Parkinson's disease with diabetes co-morbidity.
Topics: Animals; Diabetes Mellitus, Experimental; Disease Models, Animal; Hypoglycemic Agents; Male; Motor Activity; Motor Skills; Parkinson Disease, Secondary; Pyrimidines; Rats; Rats, Wistar; Rotenone; Thiazolidinediones | 2021 |
Noscapine Prevents Rotenone-Induced Neurotoxicity: Involvement of Oxidative Stress, Neuroinflammation and Autophagy Pathways.
Topics: alpha-Synuclein; Animals; Astrocytes; Autophagy; Catalase; Corpus Striatum; Dopamine; Dopaminergic Neurons; Gene Expression Regulation; Lysosomes; Male; Microglia; Neuroprotective Agents; Noscapine; Oxidative Stress; Parkinson Disease, Secondary; Pars Compacta; Rats; Rats, Wistar; Ribosomal Protein S6 Kinases, 70-kDa; Rotenone; Superoxide Dismutase; TOR Serine-Threonine Kinases | 2021 |
Ginsenoside Rg3 exerts a neuroprotective effect in rotenone-induced Parkinson's disease mice via its anti-oxidative properties.
Topics: Animals; Antioxidants; Disease Models, Animal; Ginsenosides; Humans; Male; Mice; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone; Substantia Nigra | 2021 |
Agaricus blazei extract abrogates rotenone-induced dopamine depletion and motor deficits by its anti-oxidative and anti-inflammatory properties in Parkinsonic mice.
Topics: Agaricus; Animals; Anti-Inflammatory Agents; Antioxidants; Catalase; Dopamine; Glutathione; Glutathione Peroxidase; Male; Mice; Mitochondria; Oxidative Stress; Parkinson Disease, Secondary; Rotenone; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2018 |
Assessment of gait dynamics in rotenone-induced rat model of Parkinson's disease by footprint method.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Brain Chemistry; Disease Models, Animal; Dopamine; Gait; Male; Motor Activity; Muscle Weakness; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone | 2017 |
Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease.
Topics: Adhesiveness; Administration, Intranasal; Animals; Biological Availability; Brain; Drug Delivery Systems; Gels; Humans; Male; Nasal Mucosa; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Selegiline | 2018 |
Protective effects of curcumin against rotenone-induced rat model of Parkinson's disease: in vivo electrophysiological and behavioral study.
Topics: Animals; Behavior, Animal; Curcumin; Electrophysiological Phenomena; Hippocampus; Motor Activity; Neurons; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rotenone | 2017 |
Therapeutic effects of baicalein on rotenone-induced Parkinson's disease through protecting mitochondrial function and biogenesis.
Topics: Animals; Disease Models, Animal; Flavanones; Mitochondria; Neuroprotective Agents; Organelle Biogenesis; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rotenone; Therapeutic Uses | 2017 |
The neuroprotective effects of hydro-alcoholic extract of olive (Olea europaea L.) leaf on rotenone-induced Parkinson's disease in rat.
Topics: Animals; Antioxidants; Disease Models, Animal; Dopaminergic Neurons; Lipid Peroxidation; Male; Neuroprotective Agents; Olea; Oxidative Stress; Parkinson Disease, Secondary; Plant Extracts; Plant Leaves; Rats, Wistar; Reactive Oxygen Species; Rotenone | 2018 |
Lowered iPLA
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Group VI Phospholipases A2; Humans; Lipid Peroxidation; Male; Membrane Potential, Mitochondrial; Mesencephalon; Mitochondria; Oxidative Stress; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Rotenone | 2018 |
Evaluation of antiparkinson activity of PTUPB by measuring dopamine and its metabolites in Drosophila melanogaster: LC-MS/MS method development.
Topics: Acetonitriles; Animals; Antiparkinson Agents; Biological Availability; Brain; Chromatography, High Pressure Liquid; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dopamine; Drosophila melanogaster; Epoxide Hydrolases; Formates; Humans; Male; Parkinson Disease, Secondary; Pyrazoles; Reproducibility of Results; Rotenone; Spectrometry, Mass, Electrospray Ionization; Sulfonamides; Tandem Mass Spectrometry | 2018 |
Immunomorphological Changes in the Olfactory Bulbs of Rats after Intranasal Administration of Rotenone.
Topics: Administration, Intranasal; alpha-Synuclein; Animals; Dopaminergic Neurons; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Microglia; Olfactory Bulb; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Tyrosine 3-Monooxygenase | 2017 |
[Effect of afobazole and levodopa on the activity of proline-specific proteinases and adenosine deaminase in blood serum and brain structures of rats with experimental Parkinson's syndrome induced by systemic administration of rotenone].
Topics: Adenosine Deaminase; Animals; Benzimidazoles; Brain; Dipeptidyl Peptidase 4; Levodopa; Morpholines; Parkinson Disease, Secondary; Proline; Prolyl Oligopeptidases; Rats; Rotenone; Serine Endopeptidases; Serum | 2017 |
Mitochondrial ATP-sensitive potassium channel regulates mitochondrial dynamics to participate in neurodegeneration of Parkinson's disease.
Topics: Animals; KATP Channels; Male; Mitochondria; Mitochondrial Dynamics; Mitochondrial Proteins; Parkinson Disease, Secondary; PC12 Cells; Rats; Rats, Sprague-Dawley; Rotenone | 2018 |
Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson's disease.
Topics: Animals; Colon; Diarrhea; Disease Models, Animal; Gastric Emptying; Gastrointestinal Diseases; Male; Microbiota; Parkinson Disease, Secondary; Rats; Rotarod Performance Test; Rotenone | 2018 |
Haplogroup J mitogenomes are the most sensitive to the pesticide rotenone: Relevance for human diseases.
Topics: Cell Survival; DNA, Mitochondrial; Fibroblasts; Genome, Mitochondrial; Haplotypes; Humans; Oxygen Consumption; Parkinson Disease, Secondary; Pesticides; Phylogeny; Protein Structure, Secondary; Rotenone | 2018 |
(E)-Nicotinaldehyde O-Cinnamyloxime, a Nicotine Analog, Attenuates Neuronal Cells Death Against Rotenone-Induced Neurotoxicity.
Topics: Cell Death; Cell Line, Tumor; Cell Survival; Humans; Neurons; Neuroprotective Agents; Nicotine; Oxidative Stress; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone | 2019 |
Neuroprotective effect of agmatine (decarboxylated l-arginine) against oxidative stress and neuroinflammation in rotenone model of Parkinson's disease.
Topics: Agmatine; Animals; Cytokines; Disease Models, Animal; Glial Fibrillary Acidic Protein; Glutathione; Male; Malondialdehyde; Mesencephalon; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Rats, Sprague-Dawley; Rotenone; Tyrosine 3-Monooxygenase | 2019 |
Enteric Neurodegeneration is Mediated Through Independent Neuritic and Somal Mechanisms in Rotenone and MPP+ Toxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cells, Cultured; Enteric Nervous System; Female; Insecticides; Mice; MPTP Poisoning; Nerve Degeneration; Neurites; Parkinson Disease, Secondary; Parkinsonian Disorders; Pregnancy; Rotenone | 2018 |
Parkinson's disease prevalence and the association with rurality and agricultural determinants.
Topics: Adult; Agriculture; Fabaceae; Female; Humans; Insecticides; Male; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Prevalence; Rotenone; Rural Population; Victoria | 2019 |
Simultaneous Relative Quantification of Various Polyglycerophospholipids with Isotope-Labeled Methylation by Nanoflow Ultrahigh Performance Liquid Chromatography-Tandem Mass Spectrometry.
Topics: 1-Methyl-4-phenylpyridinium; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deuterium; Humans; Isotope Labeling; Methylation; Oxidopamine; Parkinson Disease, Secondary; Phosphatidylglycerols; Rotenone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2019 |
Prophylactic neuroprotective propensity of Crocin, a carotenoid against rotenone induced neurotoxicity in mice: behavioural and biochemical evidence.
Topics: Animals; Behavior, Animal; Carotenoids; Corpus Striatum; Exploratory Behavior; Hand Strength; Male; Mice; Mitochondria; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Rotenone | 2019 |
Methyl jasmonate abrogates rotenone-induced parkinsonian-like symptoms through inhibition of oxidative stress, release of pro-inflammatory cytokines, and down-regulation of immnopositive cells of NF-κB and α-synuclein expressions in mice.
Topics: Acetates; alpha-Synuclein; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Behavior, Animal; Brain Chemistry; Cyclopentanes; Cytokines; Male; Mice; NF-kappa B; Oxidative Stress; Oxylipins; Parkinson Disease, Secondary; Psychomotor Performance; Rotenone; Uncoupling Agents | 2019 |
The role of autophagy in Parkinson's disease: rotenone-based modeling.
Topics: Apoptosis; Autophagy; Blotting, Western; Cell Death; Cell Line; Cell Proliferation; Coloring Agents; Dose-Response Relationship, Drug; Down-Regulation; Humans; Immunohistochemistry; Membrane Potential, Mitochondrial; Microscopy, Electron, Transmission; Microtubule-Associated Proteins; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone; Tetrazolium Salts; Thiazoles; Uncoupling Agents | 2013 |
[Neurotoxicity of pesticides: its relationship with neurodegenerative diseases].
Topics: alpha-Synuclein; Alzheimer Disease; Animals; Genetic Predisposition to Disease; Humans; Insecticides; Mitochondria; Neurodegenerative Diseases; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Pesticides; Rotenone | 2013 |
Sodium butyrate improves locomotor impairment and early mortality in a rotenone-induced Drosophila model of Parkinson's disease.
Topics: Animals; Animals, Genetically Modified; Butyric Acid; Disease Models, Animal; Drosophila; Histone Deacetylase Inhibitors; Motor Activity; Parkinson Disease, Secondary; Pesticides; Rotenone | 2013 |
Epidemiology. Paths from pesticides to Parkinson's.
Topics: Amyotrophic Lateral Sclerosis; Animals; Dementia; Environmental Exposure; Humans; Paraquat; Parkinson Disease; Parkinson Disease, Secondary; Pesticides; Risk Factors; Rotenone | 2013 |
Rotenone directly induces BV2 cell activation via the p38 MAPK pathway.
Topics: Animals; Cell Line; Cell Nucleus; Environmental Pollutants; Humans; I-kappa B Kinase; Inflammasomes; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Microglia; p38 Mitogen-Activated Protein Kinases; Parkinson Disease; Parkinson Disease, Secondary; Rotenone; Transcription Factor RelA | 2013 |
Sesamol and naringenin reverse the effect of rotenone-induced PD rat model.
Topics: Animals; Benzodioxoles; Disease Models, Animal; Flavanones; Male; Parkinson Disease, Secondary; Phenols; Rats; Rats, Wistar; Rotenone | 2013 |
Cell cycle regulation of DNA polymerase beta in rotenone-based Parkinson's disease models.
Topics: Animals; Cell Cycle; Cell Cycle Checkpoints; Cell Death; DNA Polymerase beta; Dopaminergic Neurons; Parkinson Disease, Secondary; Rats; Rotenone; Substantia Nigra | 2014 |
Daily rhythms of serotonin metabolism and the expression of clock genes in suprachiasmatic nucleus of rotenone-induced Parkinson's disease male Wistar rat model and effect of melatonin administration.
Topics: Animals; ARNTL Transcription Factors; Circadian Rhythm; CLOCK Proteins; Cryptochromes; Disease Models, Animal; Gene Expression; Male; Melatonin; Parkinson Disease, Secondary; Period Circadian Proteins; Rats; Rats, Wistar; Rotenone; Serotonin; Suprachiasmatic Nucleus; Time Factors | 2015 |
Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.
Topics: Animals; Brain; Dopaminergic Neurons; Encephalitis; Humans; Mitochondria; MPTP Poisoning; Neurons; Oxidative Stress; Oxidopamine; Parkinson Disease, Secondary; Rotenone; Signal Transduction | 2015 |
Rotenone decreases intracellular aldehyde dehydrogenase activity: implications for the pathogenesis of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehyde Dehydrogenase; Animals; Brain Neoplasms; Dopamine; Electron Transport Complex I; Glioblastoma; Glioma; Humans; NAD; Parkinson Disease, Secondary; PC12 Cells; Rats; Rotenone; Uncoupling Agents | 2015 |
Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.
Topics: Adamantane; Animals; Antioxidants; Apoptosis; Dopamine; Hypoglycemic Agents; Male; Motor Activity; Neuroprotective Agents; NF-E2-Related Factor 2; NF-kappa B; Nitriles; Oxidative Stress; Parkinson Disease, Secondary; Pyrrolidines; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Rotenone; Signal Transduction; Uncoupling Agents; Vildagliptin | 2015 |
Long-Term Systemic Exposure to Rotenone Induces Central and Peripheral Pathology of Parkinson's Disease in Mice.
Topics: Animals; Brain; Central Nervous System; Colon, Ascending; Dopaminergic Neurons; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Motor Neurons; Neural Pathways; Neurons; Parkinson Disease, Secondary; Peripheral Nervous System; Rotenone; Uncoupling Agents | 2015 |
Sestrin2 Protects Dopaminergic Cells against Rotenone Toxicity through AMPK-Dependent Autophagy Activation.
Topics: alpha-Synuclein; AMP-Activated Protein Kinases; Animals; Autophagy; Caspase 3; Cell Line; Dopaminergic Neurons; Nuclear Proteins; Parkinson Disease, Secondary; Rats; Rotenone; Transcriptional Activation; Uncoupling Agents; Up-Regulation | 2015 |
[Modification of experimental rotenone model of Parkinson's disease].
Topics: Animals; Behavior, Animal; Cell Count; Disease Models, Animal; Dopaminergic Neurons; Injections, Intraventricular; Male; Maze Learning; Microscopy, Electron; Mitochondria; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Stereotaxic Techniques; Substantia Nigra; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2015 |
Pyrroloquinoline quinone-conferred neuroprotection in rotenone models of Parkinson's disease.
Topics: Animals; Antioxidants; Cell Line; Cell Survival; Gene Expression Regulation; Glutathione; Humans; Malondialdehyde; Neuroprotective Agents; Parkinson Disease, Secondary; PQQ Cofactor; Rats; Rotenone; Superoxide Dismutase; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins | 2015 |
Differential pattern of motor impairments in neurotoxic, environmental and inflammation-driven rat models of Parkinson's disease.
Topics: Animals; Disease Models, Animal; Lipopolysaccharides; Neostriatum; Neurotoxins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone | 2016 |
20C, a bibenzyl compound isolated from Gastrodia elata, protects PC12 cells against rotenone-induced apoptosis via activation of the Nrf2/ARE/HO-1 signaling pathway.
Topics: Animals; Antioxidant Response Elements; Apoptosis; Bibenzyls; Gastrodia; Heme Oxygenase-1; Neuroprotective Agents; NF-E2-Related Factor 2; Oxidative Stress; Parkinson Disease, Secondary; PC12 Cells; Rats; Reactive Oxygen Species; RNA, Messenger; RNA, Small Interfering; Rotenone; Signal Transduction | 2016 |
β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease.
Topics: Animals; Cannabinoids; Dopaminergic Neurons; Male; Neuroglia; Oxidative Stress; Parkinson Disease, Secondary; Polycyclic Sesquiterpenes; Rats; Rotenone; Sesquiterpenes | 2016 |
Baicalein inhibits α-synuclein oligomer formation and prevents progression of α-synuclein accumulation in a rotenone mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Flavanones; Male; Mesencephalon; Mice; Parkinson Disease, Secondary; Protein Multimerization; Rotenone; Spinal Cord | 2016 |
Neuroprotective Effects of Germinated Brown Rice in Rotenone-Induced Parkinson's-Like Disease Rats.
Topics: Animals; Functional Food; Germination; Neuroprotective Agents; Oryza; Parkinson Disease, Secondary; Rats; Rotenone | 2016 |
Neuroprotective Effects of a Standardized Flavonoid Extract from Safflower against a Rotenone-Induced Rat Model of Parkinson's Disease.
Topics: Animals; Carthamus tinctorius; Flavonoids; Mice; Neuroprotective Agents; Parkinson Disease, Secondary; Plant Extracts; Rats; Rotenone | 2016 |
Piperine induces autophagy by enhancing protein phosphotase 2A activity in a rotenone-induced Parkinson's disease model.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Antioxidants; Autophagy; Benzodioxoles; Cell Survival; Dopaminergic Neurons; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Inbred C57BL; Mitochondria; Neuroprotective Agents; Parkinson Disease, Secondary; Piperidines; Polyunsaturated Alkamides; Protein Phosphatase 2; Rats; Rotenone; Substantia Nigra | 2016 |
Effect of Oleracein E, a Neuroprotective Tetrahydroisoquinoline, on Rotenone-Induced Parkinson's Disease Cell and Animal Models.
Topics: Alkaloids; Animals; Apoptosis; bcl-2-Associated X Protein; Body Weight; Brain; Cell Line, Tumor; Disease Models, Animal; Exploratory Behavior; Gene Expression Regulation; Humans; In Situ Nick-End Labeling; Insecticides; L-Lactate Dehydrogenase; Male; MAP Kinase Signaling System; Mice; Monoamine Oxidase; Neuroblastoma; Neuroprotective Agents; Parkinson Disease, Secondary; Phenols; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Rotenone; Statistics, Nonparametric; Tyrosine 3-Monooxygenase | 2017 |
Parkinson's disease-like motor and non-motor symptoms in rotenone-treated zebrafish.
Topics: Animals; Anxiety; Dark Adaptation; Disease Models, Animal; Gene Expression Regulation; Insecticides; Locomotion; Male; Neurotransmitter Agents; Olfaction Disorders; Parkinson Disease, Secondary; RNA, Messenger; Rotenone; Zebrafish; Zebrafish Proteins | 2017 |
Cerebellar neurochemical and histopathological changes in rat model of Parkinson's disease induced by intrastriatal injection of rotenone.
Topics: Animals; Cerebellum; Corpus Striatum; Male; Nerve Tissue Proteins; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Uncoupling Agents | 2017 |
Neuronal hemoglobin affects dopaminergic cells' response to stress.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autophagy; Brain; Dopaminergic Neurons; Epigenesis, Genetic; Gene Expression; Hemoglobins; Humans; Mice; Parkinson Disease; Parkinson Disease, Secondary; Rotenone; Substantia Nigra | 2017 |
Rifampicin pre-treatment inhibits the toxicity of rotenone-induced PC12 cells by enhancing sumoylation modification of α-synuclein.
Topics: alpha-Synuclein; Animals; Antibiotics, Antitubercular; Antiparkinson Agents; Apoptosis; Cell Survival; Parkinson Disease, Secondary; PC12 Cells; Rats; Rifampin; Rotenone; Sumoylation | 2017 |
S-nitrosylation of UCHL1 induces its structural instability and promotes α-synuclein aggregation.
Topics: alpha-Synuclein; Animals; Humans; Mice; Parkinson Disease, Secondary; Protein Aggregation, Pathological; Rotenone; Ubiquitin Thiolesterase | 2017 |
Overexpression of Kir2.3 in PC12 cells resists rotenone-induced neurotoxicity associated with PKC signaling pathway.
Topics: Animals; Apoptosis; Cell Survival; DNA; Parkinson Disease, Secondary; PC12 Cells; Potassium Channels, Inwardly Rectifying; Protein Kinase C; Rats; Rotenone; Signal Transduction; Transfection | 2008 |
Arterial baroreflex dysfunction fails to mimic Parkinson's disease in rats.
Topics: Animals; Baroreflex; Behavior, Animal; Blood Pressure; Catalepsy; Corpus Striatum; Denervation; Dopamine; Heart Rate; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Sinoatrial Node | 2008 |
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease.
Topics: Aged; Animals; Dopamine; Electron Transport Complex I; Humans; Iron; Macaca fascicularis; Macaca mulatta; Mitochondria; Neurons; Oxidation-Reduction; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Inbred Lew; Receptors, Transferrin; Rotenone; Signal Transduction; Substantia Nigra; Transferrin | 2009 |
Vascular pathology in male Lewis rats following short-term, low-dose rotenone administration.
Topics: Animals; Blood Vessels; Brain; Cerebrovascular Disorders; Disease Models, Animal; Lung; Male; Parkinson Disease, Secondary; Rats; Rats, Inbred Lew; Rotenone | 2009 |
Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Cell Count; Disease Models, Animal; ELAV Proteins; Enteric Nervous System; Gastric Emptying; Gastrointestinal Motility; Isometric Contraction; Male; Motor Activity; Muscle, Smooth; Neurons; Parkinson Disease, Secondary; Rats; Rats, Inbred Lew; Rotenone; Stomach Diseases; Time Factors; Tyrosine 3-Monooxygenase | 2009 |
Tranexamic acid protects against rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells.
Topics: Antifibrinolytic Agents; Apoptosis; bcl-2-Associated X Protein; Caspases; Cell Line, Tumor; Cell Survival; Chemoprevention; Enzyme Induction; Humans; Insecticides; JNK Mitogen-Activated Protein Kinases; Neuroblastoma; Neurons; p38 Mitogen-Activated Protein Kinases; Parkinson Disease, Secondary; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Dopamine; Rotenone; Tranexamic Acid | 2009 |
Induction of heat shock protein 70 reduces the alteration of striatal electrical activity caused by mitochondrial impairment.
Topics: Animals; Corpus Striatum; Electron Transport Complex I; Electron Transport Complex II; Heat-Shock Response; HSP70 Heat-Shock Proteins; Huntington Disease; In Vitro Techniques; Male; Mitochondria; Neurons; Nitro Compounds; Parkinson Disease, Secondary; Patch-Clamp Techniques; Propionates; Rats; Rats, Wistar; Rotenone | 2009 |
Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein.
Topics: alpha-Synuclein; Analysis of Variance; Animals; Brain; Cell Death; Chromatography, High Pressure Liquid; Disease Models, Animal; DNA Fragmentation; Dopamine; Drug Administration Schedule; Gene Expression Regulation; Histone Deacetylases; Immunoprecipitation; Insecticides; Male; Molecular Weight; Neuroprotective Agents; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Valproic Acid | 2010 |
Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models.
Topics: Adenosine Triphosphate; Animals; Behavior, Animal; Cell Line; Cell Line, Tumor; Disease Models, Animal; Humans; Hydrogen Sulfide; Lipid Metabolism; Male; MAP Kinase Signaling System; NADPH Oxidases; Neuroprotective Agents; NF-kappa B; Oxidation-Reduction; Oxidopamine; Oxygen Consumption; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone | 2010 |
Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Depression; Disease Models, Animal; Dopamine; Hippocampus; Lipopolysaccharides; Male; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Random Allocation; Rats; Rats, Wistar; Rotenone; Serotonin | 2010 |
Progressive loss of dopaminergic neurons induced by unilateral rotenone infusion into the medial forebrain bundle.
Topics: alpha-Synuclein; Animals; Apoptosis; Astrocytes; Calcium-Binding Proteins; Caspase 3; Cell Count; Densitometry; Disease Models, Animal; Dopamine; Glial Fibrillary Acidic Protein; Immunohistochemistry; Male; Medial Forebrain Bundle; Microfilament Proteins; Microglia; Neurons; Oxidative Stress; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Superoxide Dismutase; Synapses; Synaptophysin; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2010 |
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection.
Topics: Animals; Cell Line; Electron Transport Chain Complex Proteins; Enzyme Inhibitors; Glycolysis; Male; Methylene Blue; Mitochondria; Neurons; Neuroprotective Agents; Oxygen Consumption; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra; Uncoupling Agents | 2011 |
Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson's disease.
Topics: Acetylcholinesterase; Animals; Antioxidants; Carotenoids; Cognition; Cytochromes c; Disease Models, Animal; Humans; Lycopene; Male; NADH Dehydrogenase; Neuropsychological Tests; Oxidative Stress; Parkinson Disease, Secondary; Random Allocation; Rats; Rats, Wistar; Rotenone; Uncoupling Agents | 2011 |
Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease.
Topics: Animals; Antineoplastic Agents; Antioxidants; Disease Models, Animal; Hypoglycemic Agents; Male; Motor Activity; Neuroprotective Agents; Parkinson Disease, Secondary; Pioglitazone; Rats; Rats, Wistar; Rotenone; Thiazolidinediones; Tretinoin | 2011 |
Rotenone and paraquat linked to Parkinson's disease: human exposure study supports years of animal studies.
Topics: Herbicides; Humans; Insecticides; Paraquat; Parkinson Disease, Secondary; Rotenone; United States | 2011 |
Mitochondrial dysfunction precedes other sub-cellular abnormalities in an in vitro model linked with cell death in Parkinson's disease.
Topics: Cell Death; Cell Line, Tumor; Humans; Lysosomes; Mitochondria; Naphthoquinones; Neurons; Parkinson Disease, Secondary; Proteasome Endopeptidase Complex; Rotenone; Time Factors; Ubiquitin | 2012 |
Protective effect of Bu-7, a flavonoid extracted from Clausena lansium, against rotenone injury in PC12 cells.
Topics: Animals; Apoptosis; Cell Survival; Clausena; Flavonoids; Insecticides; Membrane Potential, Mitochondrial; Parkinson Disease, Secondary; PC12 Cells; Plant Extracts; Rats; Rotenone | 2011 |
Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Dependovirus; Disease Models, Animal; Male; Neurons; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra | 2012 |
Glycogen synthase kinase-3β activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization.
Topics: Cell Line, Tumor; Electron Transport Complex I; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Microtubules; Paclitaxel; Parkinson Disease, Secondary; Phosphorylation; Reactive Oxygen Species; Rotenone; tau Proteins; Tubulin Modulators | 2012 |
Mitochondrial dysfunction and oxidative stress promote apoptotic cell death in the striatum via cytochrome c/caspase-3 signaling cascade following chronic rotenone intoxication in rats.
Topics: Animals; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Caspase 3; Corpus Striatum; Cytochromes c; Insecticides; Male; Membrane Proteins; Mitochondria; Oxidative Stress; Parkinson Disease, Secondary; Proto-Oncogene Proteins; Rats; Rats, Inbred Lew; Rotenone; Signal Transduction | 2012 |
Anti-inflammatory properties rather than anti-oxidant capability is the major mechanism of neuroprotection by sodium salicylate in a chronic rotenone model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Inflammatory Agents; Antioxidants; Brain; Catalase; Cytokines; Dopamine; Homovanillic Acid; Inflammation; Male; Monoamine Oxidase; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Rotenone; Sodium Salicylate | 2013 |
Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice.
Topics: alpha-Synuclein; Animals; Axonal Transport; Brain; Enteric Nervous System; Humans; Insecticides; Mice; Neurons; Parkinson Disease, Secondary; Primary Cell Culture; Rotenone; Sympathectomy; Vagotomy | 2012 |
Characterization of motor, depressive-like and neurochemical alterations induced by a short-term rotenone administration.
Topics: Animals; Brain Chemistry; Depression; Dopamine; Male; Motor Activity; Norepinephrine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotenone; Serotonin | 2012 |
Using human pluripotent stem cell-derived dopaminergic neurons to evaluate candidate Parkinson's disease therapeutic agents in MPP+ and rotenone models.
Topics: 1-Methyl-4-phenylpyridinium; Antiparkinson Agents; Cell Differentiation; Cells, Cultured; Dopaminergic Neurons; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Humans; Microarray Analysis; Models, Theoretical; Neurogenesis; Neuroprotective Agents; Parkinson Disease, Secondary; Pluripotent Stem Cells; Rotenone | 2013 |
An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Respiration; Cytochrome c Group; DNA Damage; Drug Synergism; Electron Transport Complex I; Enzyme Inhibitors; Glutathione; Humans; Hydrogen Peroxide; Mitochondria; NADH, NADPH Oxidoreductases; Nerve Tissue Proteins; Neuroblastoma; Neurons; Oxidants; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Rotenone; Synucleins; Time; Tumor Cells, Cultured; Ubiquitin; Uncoupling Agents | 2002 |
Activation of adenosine triphosphate-sensitive potassium channels confers protection against rotenone-induced cell death: therapeutic implications for Parkinson's disease.
Topics: Adenosine Triphosphate; Animals; Cell Death; Dose-Response Relationship, Drug; Electron Transport Complex I; Ferrous Compounds; Glyburide; Ischemic Preconditioning; Mitochondria; NADH, NADPH Oxidoreductases; Neurons; Parkinson Disease; Parkinson Disease, Secondary; PC12 Cells; Pinacidil; Potassium Channel Blockers; Potassium Channels; Protein Synthesis Inhibitors; Rats; Rotenone; Uncoupling Agents; Vasodilator Agents; Xanthine; Xanthine Oxidase | 2002 |
Pesticide-Parkinson link explored.
Topics: Animals; Environmental Exposure; Humans; Insecticides; Lewy Bodies; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Pesticides; Rats; Rotenone | 2002 |
Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.
Topics: Animals; Behavior, Animal; Blotting, Western; Catalepsy; Chromatography, High Pressure Liquid; Dopamine; Electrochemistry; Immunohistochemistry; Male; Neostriatum; Neurons; Parkinson Disease, Secondary; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Rotenone; Tyrosine 3-Monooxygenase; Uncoupling Agents | 2002 |
Rotenone induces non-specific central nervous system and systemic toxicity.
Topics: Animals; Brain; Disease Models, Animal; Dopamine; Motor Activity; Neurodegenerative Diseases; Neurons; Parkinson Disease, Secondary; Rats; Rotenone | 2004 |
Sleep disturbances in the rotenone animal model of Parkinson disease.
Topics: Animals; Disease Models, Animal; Male; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Sleep Wake Disorders | 2005 |
Chromatographic analysis of dopamine metabolism in a Parkinsonian model.
Topics: Adenine Nucleotides; Animals; Catecholamines; Chromatography, Liquid; Corpus Striatum; Dopamine; Insecticides; Male; Models, Chemical; Molecular Structure; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone | 2006 |
Geographic isolates of atypical Parkinsonism and tauopathy in the tropics: possible synergy of neurotoxins.
Topics: Acetogenins; Amino Acids, Diamino; Annonaceae; Cyanobacteria Toxins; Drug Synergism; Fatty Alcohols; Guadeloupe; Guam; Humans; Japan; Lactones; Motor Neuron Disease; Neurotoxins; Parkinson Disease, Secondary; Rotenone; Tauopathies; Tropical Climate | 2006 |
Caenorhabditis elegans MPP+ model of Parkinson's disease for high-throughput drug screenings.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Caenorhabditis elegans; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Green Fluorescent Proteins; Mitochondria; Motor Activity; Neurons; Parkinson Disease, Secondary; Phenotype; Rotenone; Uncoupling Agents | 2004 |
D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease.
Topics: 3-Hydroxybutyric Acid; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Dopamine; Fluorescent Dyes; Humans; Indoles; Ketone Bodies; L-Lactate Dehydrogenase; Membrane Potentials; Neurons; Neurotoxins; Nitro Compounds; Oxidation-Reduction; Parkinson Disease, Secondary; Propionates; Rotenone; Succinates; Uncoupling Agents | 2006 |
Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Administration, Inhalation; Administration, Intranasal; Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Drug Administration Schedule; Herbicides; Insecticides; Male; Mice; Mice, Inbred C57BL; Motor Activity; Nerve Degeneration; Neurons; Paraquat; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Rotenone; Substantia Nigra | 2007 |
Neurotoxicity of nicotinamide derivatives: their role in the aetiology of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Humans; Isomerism; Kinetics; L-Lactate Dehydrogenase; Neuroblastoma; Neurotoxins; Niacinamide; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rotenone; Tumor Cells, Cultured | 1993 |
Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease.
Topics: Animals; Antimetabolites; Apoptosis; Behavior, Animal; Carrier Proteins; Corpus Striatum; Deoxyglucose; Disease Models, Animal; Dopamine; Dopamine Agents; Endoplasmic Reticulum Chaperone BiP; Energy Intake; Ferrous Compounds; Heat-Shock Proteins; Heat-Shock Response; HSP70 Heat-Shock Proteins; Male; Mice; Mice, Inbred C57BL; Mitochondria; Molecular Chaperones; MPTP Poisoning; Nerve Degeneration; Neurons; Parkinson Disease, Secondary; Reactive Oxygen Species; Rotenone; Substantia Nigra; Uncoupling Agents | 1999 |
1-Methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) is toxic to dopaminergic neuroblastoma SH-SY5Y cells via impairment of cellular energy metabolism.
Topics: 1-Methyl-4-phenylpyridinium; Adenosine Triphosphate; Dopamine; Dose-Response Relationship, Drug; Electron Transport Complex I; Electron Transport Complex II; Energy Metabolism; Glucose; Herbicides; Humans; Isoquinolines; Mitochondria; Multienzyme Complexes; NAD; NADH, NADPH Oxidoreductases; Neuroblastoma; Oxidoreductases; Parkinson Disease, Secondary; Rotenone; Succinate Dehydrogenase; Tumor Cells, Cultured; Uncoupling Agents | 2000 |
Pesticide use linked to Parkinson's disease.
Topics: Adult; Animals; Environmental Exposure; Humans; Insecticides; Middle Aged; Parkinson Disease, Secondary; Rats; Rotenone | 2000 |
A new link between pesticides and Parkinson's disease.
Topics: Animals; Environmental Exposure; Humans; Lewy Bodies; Nerve Tissue Proteins; Parkinson Disease; Parkinson Disease, Secondary; Pesticides; Rotenone; Synucleins | 2000 |
Chronic systemic pesticide exposure reproduces features of Parkinson's disease.
Topics: Animals; Dopamine; Dyskinesias; Electron Transport Complex I; Environmental Exposure; Lewy Bodies; Male; NADH, NADPH Oxidoreductases; Neostriatum; Nerve Degeneration; Neural Pathways; Neurons; Parkinson Disease; Parkinson Disease, Secondary; Presynaptic Terminals; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Rotenone; Substantia Nigra | 2000 |
Rats and risk.
Topics: Animals; Food; Genetic Engineering; Humans; Insecticides; Journalism; Parkinson Disease, Secondary; Rats; Risk; Rotenone | 2001 |
Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biomarkers; Brain; Cell Survival; Corpus Striatum; Diet; Dopamine; Drug Synergism; Folic Acid Deficiency; Homocysteine; Humans; Hyperhomocysteinemia; Iron; Male; Mice; Mice, Inbred C57BL; Mitochondria; Motor Activity; Neurons; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Rotenone; Tumor Cells, Cultured | 2002 |
Selected presentations and general discussion: session IX summary and research needs.
Topics: Animals; Dopamine; Humans; Neurotoxicity Syndromes; Parkinson Disease; Parkinson Disease, Secondary; Polychlorinated Biphenyls; Rotenone; Saimiri; Thiocarbamates; Uncoupling Agents | 2001 |